-5.5%
ETN vs MRNA
+945.0%
-950.5%
-23.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -9.9% | +13.1% | -23.0% | -9.9% |
| 7D | -10.1% | +20.6% | -30.8% | -10.2% |
| 30D | -18.4% | +27.1% | -45.5% | -18.5% |
| 3M | -20.4% | +353.4% | -373.8% | -21.4% |
| 6M | -16.0% | +446.3% | -462.2% | -19.7% |
| YTD | +11.8% | +776.2% | -764.4% | -1.3% |
| 1Y | -5.5% | +987.9% | -993.4% | -21.4% |
| All | -5.5% | +945.0% | -950.5% | -21.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling